◆ 会议时间：2025年4月2-5号
◆ 会议地点：英国 格拉斯哥

◆ 会议简介：

第32届国际先进脊柱外科技术会议(IMAST)将于2025年4月2-5号在英国格拉斯哥举行，会议由脊柱侧凸研究学会（SRS）主办。IMAST是一个聚集一流脊柱外科医生、创新研究与最先进脊柱外科技术的国际会议。三天的会义，来自世界各地的外科医生将讨论、辩论和演示最新的脊柱外科技术，以帮助彼此改善患者护理。大会议题将聚焦治疗各种脊柱疾病的新技术和先进技术。

脊柱侧凸研究学会（SRS）成立于1966年，是国际公认的世界上最权威的脊柱学会之一，专业致力于促进脊柱畸形领域宣的研究和教育。SRS拥有极其严格的会员资格标准，目前拥有超过1000名来自各地的最优秀的脊柱外科医生、从事脊柱畸形研究与治疗的研究人员、医生助理和矫形师会员，他们在各自专业领域内为提高脊柱畸形患者的诊治水平做出了巨大的贡献。SRS每年举办一次全球会议（年会），总结、汇报、交流、讨论当年脊柱畸形（主要为脊柱侧、后凸畸形）领域诊治及研究的成果以及新进展，进而促进全世界范围内脊柱侧凸诊治水平的不断提高。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）

IMAST 2025 - 32nd International Meeting on Advance Spine Techniques

Date: April 2 - 5, 2025
Location: Glasgow, Scotland, UK

Organized by: Scoliosis Research Society

以下为上届会议信息

摘要征文投稿：

Key Dates

*dates are subject to change

点此提交摘要>>>Submit Abstract>>>

Submit Your Disclosure

Abstract Categories

Abstract submission to IMAST must fit into one of the following categories to be considered for presentation. Authors can choose optional sub-categories to further classify their topic. More than one sub-category can be selected:

Abstract Length

• Maximum of 2,250 characters
• Characters in the abstract title, body and table/image caption will be counted (including spaces)  
• Characters in the author and institution listing will not be counted.  
• Limited to one graph, figure, or table for each submitted abstract. No exceptions will be made.  

Disclosure and Licensing Requirement

ALL authors listed on an abstract will be required to submit a:

• Financial disclosure form, including disclosure of ALL financial relationships, not only those pertaining to the topic of the abstract, from the past 24 months.  
• FDA Disclosure Form  
• Attestation and Non-exclusive License Form   

If authors on an abstract have not completed these required forms prior to the submission deadline, the abstract will NOT be reviewed or considered for the meeting program.

*Abstracts with authors missing a completed Financial Relationship Disclosure will NOT be reviewed.

Visit this link to disclose: https://owpm1.com/abstracts/IMAST/disclosure  

The username is the email associated with your abstract and the password your first name.

Previous Publication or Presentation

Abstracts which have been published in journals, meeting proceedings, or other publications, as well as those presented at meetings prior to the SRS meeting to which authors wish to submit, are NOT eligible for submission. Only abstracts that have NOT been previously published or presented are eligible for submission.

Product-Specific Language

SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, ROTEM, Isola, TSRH, CD, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque).

It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any potential conflict of interest. When there is a known potential conflict of interest, expanded verbal disclosure will be necessary at the time of presentation.

Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.

Abstract Review

All abstracts submitted will be reviewed and graded in blinded fashion by the IMAST Committee. Two-year follow-up is required for papers submitted to the Annual Meeting. Based upon abstract grading, those selected will be assigned to a four-minute oral presentation or three-minute E-Point presentation. Acceptance notification will be sent in December 2023.

Author Requirements

Attendance

By submitting an abstract to the Annual Meeting, abstract authors agree that at least one (1) author will attend the meeting and will be available to present on the date and time assigned.  

In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth will automatically be withdrawn from the program.

All travel arrangements are the responsibility of the authors.  

Acceptance

All selected authors will be required to respond to a formal invitation by the deadline set forth in their acceptance notification.  

Authors without an account AND an updated disclosure cannot be added after this date. No exceptions will be made.

Podium Presentation Cancellation & No-Show Policy

Authors unable to present their paper in person should inform SRS as soon as possible with a co-author that can attend to present the paper. If no one can attend in person, please inform SRS by January, so an alternate paper can be substituted.

Please note: In the case of a "no-show" podium presentation, the presenting author associated with the "no-show" paper will be prohibited from presenting any papers at the next two Annual Meetings.

E-Point Presentation Cancellation Policy

At least one author or co-author on all E-Point presentations is expected to register to attend the meeting by the deadline set forth in their acceptance notification.  
If this author cancels their registration prior to the meeting, the E-Point presentation may be withdrawn from the program.

CME Review

All presentations must clear a CME review conducted by the SRS CME Committee. Presenters may be required to submit slides for review before the meeting and may be asked to make small or significant changes if a bias issue is found.

Failure to address pertinent CME review issues will result in pulling the presentation from the program and in a one-year ban for abstract presentations and a three-year ban for invited presentations.

注册费：

Meeting Pricing

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。